Clinical Trial: Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07531095) titled 'Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)' on April 09.

Brief Summary: The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.

Study Start Date: May 05

Study Type: INTERVENTIONAL

Condition: Small Cell Lung Cancer

Intervention: DRUG: ZL-1310

ZL-1310 will be administered as an IV infusion.

DRUG: Tarlatamab

Tarlatamab will be...